股本结构
单位:万股
公告日期 | 2023-08-08 | 2023-03-15 | 2023-01-26 | 2022-03-18 | 2021-08-16 | 2021-03-24 |
---|---|---|---|---|---|---|
证券总股本 | 324.95 | 310.42 | 310.43 | 3104.26 | 2994.40 | 2994.38 |
普通股本 | 324.95 | 310.42 | 310.43 | 3104.26 | 2994.40 | 2994.38 |
优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
变动日期 | 2023-06-30 | 2023-03-07 | 2023-02-01 | 2021-12-31 | 2021-08-12 | 2020-12-31 |
注释:中概股证券总股本=普通股股本/
存托凭证比例
历史变动
公告日期 | 变动后普通股本(万股) | 变动后优先股(万股) | 变动原因 | 变动日期 |
---|---|---|---|---|
2023-08-08 | 324.95 | 未披露 | 定期报告 | 2023-06-30 |
2023-03-15 | 310.42 | 未披露 | 定期报告 | 2023-03-07 |
2023-01-26 | 310.43 | 未披露 |
更多>>
Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that a consolidation of all of the issued and outstanding common shares of the Company ("Common Shares") on the basis of a consolidation ratio of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the "Share Consolidation"), will become effective at the opening of trading on February 1, 2023 (the "Effective Date").
|
2023-02-01 |
2022-03-18 | 3104.26 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Shares issued upon conversion of debt
|
2021-12-31 |
2021-08-16 | 2994.40 | 未披露 | 定期报告 | 2021-08-12 |
2021-03-24 | 2994.38 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Issuance of shares
Exercise of stock options
Shares issued pursuant to restricted share units plan
Exercise of warrants
|
2020-12-31 |
2020-11-12 | 2938.59 | 未披露 | 定期报告 | 2020-11-09 |
2020-12-01 | 2362.81 | 未披露 |
更多>>
From December 31, 2019 to August 31, 2020
Issued to acquire assets
Exercise of stock options
Shares issued pursuant to a restricted share units plan
|
2020-08-31 |
2020-08-13 | 2362.53 | 未披露 | 定期报告 | 2020-07-31 |
2020-05-13 | 2342.04 | 未披露 |
更多>>
from December 31, 2019 to March 19, 2020
Issued to acquire assets
Shares issued pursuant to a restricted share units plan
|
2020-03-19 |
2020-03-20 | 2331.32 | 未披露 |
更多>>
From December 31, 2018 to November 18, 2019
Issued to acquire assets
Shares issued pursuant to debt restructuring
Shares issued for cash
Shares issued in payment to suppliers
|
2019-11-18 |
Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that a consolidation of all of the issued and outstanding common shares of the Company ("Common Shares") on the basis of a consolidation ratio of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the "Share Consolidation"), will become effective at the opening of trading on February 1, 2023 (the "Effective Date").
From December 31, 2020 to December 31, 2021
Shares issued upon conversion of debt
from December 31, 2019 to December 31, 2020
Issuance of shares
Exercise of stock options
Shares issued pursuant to restricted share units plan
Exercise of warrants
From December 31, 2019 to August 31, 2020
Issued to acquire assets
Exercise of stock options
Shares issued pursuant to a restricted share units plan
from December 31, 2019 to March 19, 2020
Issued to acquire assets
Shares issued pursuant to a restricted share units plan
From December 31, 2018 to November 18, 2019
Issued to acquire assets
Shares issued pursuant to debt restructuring
Shares issued for cash
Shares issued in payment to suppliers